PALI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
-100.0%
500.0K
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
500.0K
0
0
0
Operating Expenses
15.7M
+28.7%
12.2M
+13.5%
10.7M
+7.7%
10.0M
+241.6%
2.9M
R&D
10.6M
+43.0%
7.4M
+15.7%
6.4M
+3.6%
6.2M
+342.8%
1.4M
SG&A
5.1M
+6.7%
4.8M
+10.3%
4.4M
+14.3%
3.8M
+149.2%
1.5M
Operating Income
-15700000
-34.2%
-11698000
-8.8%
-10748000
-7.7%
-9981000
-241.6%
-2922000
EBITDA
-15700000
-34.2%
-11698000
-8.8%
-10748000
-7.7%
-9981000
-241.7%
-2921000
Net Income
-14623000
-38.3%
-10574000
-10.1%
-9600000
-7.9%
-8899000
-210.3%
-2868000
EPS (Basic)
$-0.07
-40.0%
$-0.05
+0.0%
$-0.05
-25.0%
$-0.04
+89.5%
$-0.38
EPS (Diluted)
$-0.07
-40.0%
$-0.05
+0.0%
$-0.05
-25.0%
$-0.04
+89.5%
$-0.38
Shares (Diluted)
212.0M
+0.3%
211.4M
+0.8%
209.7M
+2.0%
205.6M
+2651.1%
7.5M
Palisade Bio (PALI) — Financials